Researchers at Cincinnati Children's have identified a potential new way to relieve chronic pain linked to neurofibromatosis ...

The rare genetic disorder neurofibromatosis, or NF, affects about 1 in every 3,000 people and causes tumors to grow along nerves throughout the body.

Genetic diseases are persistent and often cause minor issues that can develop into more prominent problems later. Take neurofibromatosis type one, a common genetic disorder where a “loss of function” ...

Zoe Petropoulos and her family's years of fundraising into neurofibromatosis research seems to be bearing fruit with a ...

Health experts underscore that early detection of Neurofibromatosis Type 1 (NF1) signs and symptoms is essential for proper patient management and timely specialist referrals. Subsequent monitoring is ...

"In his legacy and his honor, we’re trying our hardest to wipe this disease off the planet," Gilbert said ...

Kristi Saylor calls neurofibromatosis "the most common genetic disorder that no one has ever heard of." She wants to change that.  Saylor is the co-organizer of a fundraising walk Saturday in Columbia ...

Excluding NF1-specific cancers, the SMR in the study by Uusitalo et a 16 l was 2.25 overall, 2.01 for men, and 2.48 for women. The increased SMR in women is driven, in part, by the 5.2-fold SMR for ...

The Dirt Road Mafia hobbyist group unanimously decided to focus its yearly fundraiser on Kristy Jackson, who lives with a ...

Neurofibromatosis type 1 (NF1) is a genetic condition that raises your risk of tumors, including benign plexiform neurofibromas (PN), which grow along tissues that cover nerves. PN often can’t be ...

Neurofibromatosis 2 (NF2) is a rare genetic disorder that causes noncancerous tumors on nerves in the brain and spinal cord. These tumors can affect hearing, vision, and balance. About half of the ...

“Why are non-disabled people writing about disability without consultation?” the British actor said Vanessa Etienne is a Staff Writer for PEOPLE on the Health team. She joined the brand in 2021. Matt ...